Lyophilised Powder
Retatrutide 10mg
Triple Receptor Agonist — GLP-1 / GIP / Glucagon
Product Description
Retatrutide (LY3437943) is a novel triple receptor agonist currently under advanced clinical investigation. It acts simultaneously on glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This multi-receptor mechanism distinguishes it from dual agonists and positions it as a subject of significant interest in metabolic research.
Each PeakLab Australia vial contains 10mg of lyophilised Retatrutide peptide, synthesised to ≥99% purity as verified by HPLC analysis. A Certificate of Analysis (CoA) is provided with every order, documenting purity, molecular weight confirmation, and sterility testing results.
This product is supplied strictly for in vitro and laboratory research purposes only. It is not intended for human or veterinary use, and is not a therapeutic good approved by the Therapeutic Goods Administration (TGA).
Research Context
Retatrutide has been the subject of Phase 2 clinical trials investigating its effects on body weight, glycaemic control, and metabolic parameters. Published data from Eli Lilly's research programme (NEJM, 2023) demonstrated substantial reductions in body weight over 48-week periods in trial participants. Researchers have noted its differentiated mechanism compared to semaglutide and tirzepatide, attributing enhanced efficacy to the additional glucagon receptor component.
